Market capitalization | $6.49m |
Enterprise Value | $63.59m |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.25 |
P/S ratio (TTM) P/S ratio | 0.03 |
Revenue growth (TTM) Revenue growth | -5.38% |
Revenue (TTM) Revenue | $257.55m |
EBIT (operating result TTM) EBIT | $42.46m |
Free Cash Flow (TTM) Free Cash Flow | $-9.39m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:
2 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:
Jun '23 |
+/-
%
|
||
Revenue | 258 258 |
5%
5%
|
|
Gross Profit | 180 180 |
10%
10%
|
|
EBITDA | 64 64 |
14%
14%
|
EBIT (Operating Income) EBIT | 42 42 |
39%
39%
|
Net Profit | 12 12 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
Head office | United States |
CEO | Michael Graves |
Founded | 2007 |
Website | www.eagleus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.